A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.

Dennison, Sheri K; Jacobs, Samuel A; Wilson, John W; Seeger, Janell; Cescon, Terrence P; Raymond, Jane M; Geyer, Charles E; Wolmark, Norman; Swain, Sandra M

Dennison, Sheri K; Jacobs, Samuel A; Wilson, John W; Seeger, Janell; Cescon, Terrence P; Raymond, Jane M; Geyer, Charles E; Wolmark, Norman; Swain, Sandra M.

Affiliation

Dennison SK; Walter Reed Army Medical Center, 6900 Georgia Ave. NW, Washington, DC 20307, USA. dennisonsk@mail.nih.gov

Invest New Drugs ; 25(6): 545-51, 2007 Dec.

Article in En | MEDLINE | ID: mdl-17563856

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/pathology; Breast Neoplasms, Male/drug therapy; Breast Neoplasms, Male/pathology; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia/chemically induced; Quinazolines/administration & dosage; Taxoids/administration & dosage; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2007 Type: Article Affiliation country: United States

Search on Google

Add to My VHL

XML

PubMed Links